RxDoctor Payments Data

Jennifer Bala, MD

Nephrology · Bradenton, FLNPI 1831377399

Payments from drug & device makers

$2,736in general payments, 2019–2025

Across 36 payments — averaging $75.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nuwellis, Inc.$393
  • AstraZeneca$348
  • Fresenius USA Marketing, Inc.$311
  • Travere Therapeutics, Inc.$280
  • Bard Peripheral Vascular, Inc.$197
  • Bayer$173
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$2,736100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,736 in reported general payments places this provider in the 60th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$229,643
Medicare patients
542
Services billed
1,905

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol38$40,936
JardianceEmpagliflozin31$32,702
LokelmaSodium Zirconium Cyclosilicate12$11,139
Nifedipine ErNifedipine33$1,401
Hydralazine Hcl39$1,215
Mycophenolate Mofetil16$884
Calcitriol25$697
Valsartan29$615
Furosemide63$610
Carvedilol14$543
Losartan Potassium34$499
Spironolactone17$353
Amlodipine Besylate31$248
Allopurinol39$209
Metoprolol Succinate15$207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$348$52,07650 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 756 nephrology providers in Florida.

Other nephrology in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →